Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as DVS-233 SR, DVS-233 SR (desvenlafaxine sustained release )
DVS-233 · 11 trials · 7 indications
| Name | Type | Description |
|---|---|---|
| DVS-233 | DRUG | - |
| DVS-233 SR | DRUG | - |
| DVS-233 SR (desvenlafaxine sustained release ) | DRUG | - |
| Venlafaxine ER | DRUG | - |
Inclusion Criteria: * Postmenopausal women of age 40 to 65 seeking treatment for hot flashes with last natural menstrual period (LNMP) completed at least 12 months prior to screening. * Minimum of 7 moderate to severe hot flashes per day or 50 per week recorded for 7 consecutive days * Body Mass In...
DVS-233 is an investigational small molecule developed by Pfizer, Inc. (PFE) for major depressive disorder and vasomotor symptoms associated with menopause. It is also known as DVS-233 SR, or desvenlafaxine sustained release. It has been studied in Phase 3 clinical trials.
DVS-233 is being developed for the treatment of major depressive disorder and for vasomotor symptoms associated with menopause. It has been evaluated in Phase 3 trials for these conditions, including studies in outpatients with depression and in women experiencing menopausal hot flashes.
DVS-233 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer is the sponsor of the clinical trials evaluating DVS-233 for major depressive disorder and menopausal vasomotor symptoms.
DVS-233 is in Phase 3 clinical development. Seven Phase 3 trials have been completed, and no active trials are currently listed. The completed studies enrolled a total of 2,443 participants and evaluated DVS-233 for major depressive disorder and menopausal vasomotor symptoms.
DVS-233 has been studied in completed Phase 3 trials including NCT00452595 in major depressive disorder, NCT00421031 and NCT00256685 in menopausal vasomotor symptoms, and NCT00195546 in menopause. These trials were randomized and double-blind, with some conducted across multiple countries.
Yes, DVS-233 SR is an alternative name for DVS-233. It is also known as desvenlafaxine sustained release. The SR designation refers to the sustained-release formulation used in the clinical development program for major depressive disorder and menopausal vasomotor symptoms.